nodes	percent_of_prediction	percent_of_DWPC	metapath
Avanafil—Muscle spasms—Etoposide—testicular cancer	0.00296	0.00296	CcSEcCtD
Avanafil—Body temperature increased—Bleomycin—testicular cancer	0.00294	0.00294	CcSEcCtD
Avanafil—Hypoglycaemia—Epirubicin—testicular cancer	0.00293	0.00293	CcSEcCtD
Avanafil—Dizziness—Vinblastine—testicular cancer	0.00291	0.00291	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.00289	0.00289	CcSEcCtD
Avanafil—Pain in extremity—Epirubicin—testicular cancer	0.00286	0.00286	CcSEcCtD
Avanafil—Myalgia—Cisplatin—testicular cancer	0.00286	0.00286	CcSEcCtD
Avanafil—Nausea—Chlorambucil—testicular cancer	0.00285	0.00285	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00284	0.00284	CcSEcCtD
Avanafil—Hot flush—Doxorubicin—testicular cancer	0.00283	0.00283	CcSEcCtD
Avanafil—Somnolence—Ifosfamide—testicular cancer	0.00282	0.00282	CcSEcCtD
Avanafil—Menopausal symptoms—Doxorubicin—testicular cancer	0.00281	0.00281	CcSEcCtD
Avanafil—Vomiting—Vinblastine—testicular cancer	0.0028	0.0028	CcSEcCtD
Avanafil—Breast disorder—Methotrexate—testicular cancer	0.00276	0.00276	CcSEcCtD
Avanafil—Vertigo—Etoposide—testicular cancer	0.00276	0.00276	CcSEcCtD
Avanafil—Headache—Vinblastine—testicular cancer	0.00276	0.00276	CcSEcCtD
Avanafil—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00274	0.00274	CcSEcCtD
Avanafil—Body temperature increased—Dactinomycin—testicular cancer	0.00274	0.00274	CcSEcCtD
Avanafil—Fatigue—Ifosfamide—testicular cancer	0.00274	0.00274	CcSEcCtD
Avanafil—Infection—Cisplatin—testicular cancer	0.00272	0.00272	CcSEcCtD
Avanafil—Constipation—Ifosfamide—testicular cancer	0.00272	0.00272	CcSEcCtD
Avanafil—Hypoglycaemia—Doxorubicin—testicular cancer	0.00271	0.00271	CcSEcCtD
Avanafil—Nervous system disorder—Cisplatin—testicular cancer	0.00269	0.00269	CcSEcCtD
Avanafil—Cough—Etoposide—testicular cancer	0.00268	0.00268	CcSEcCtD
Avanafil—Blood creatinine increased—Epirubicin—testicular cancer	0.00268	0.00268	CcSEcCtD
Avanafil—Tachycardia—Cisplatin—testicular cancer	0.00267	0.00267	CcSEcCtD
Avanafil—Asthenia—Bleomycin—testicular cancer	0.00267	0.00267	CcSEcCtD
Avanafil—Skin disorder—Cisplatin—testicular cancer	0.00266	0.00266	CcSEcCtD
Avanafil—Hypertension—Etoposide—testicular cancer	0.00265	0.00265	CcSEcCtD
Avanafil—Pain in extremity—Doxorubicin—testicular cancer	0.00265	0.00265	CcSEcCtD
Avanafil—Pruritus—Bleomycin—testicular cancer	0.00263	0.00263	CcSEcCtD
Avanafil—Chest pain—Etoposide—testicular cancer	0.00262	0.00262	CcSEcCtD
Avanafil—Nausea—Vinblastine—testicular cancer	0.00261	0.00261	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.0026	0.0026	CcSEcCtD
Avanafil—Breast disorder—Epirubicin—testicular cancer	0.00259	0.00259	CcSEcCtD
Avanafil—Hypotension—Cisplatin—testicular cancer	0.00256	0.00256	CcSEcCtD
Avanafil—Nasopharyngitis—Epirubicin—testicular cancer	0.00256	0.00256	CcSEcCtD
Avanafil—Abdominal discomfort—Methotrexate—testicular cancer	0.00253	0.00253	CcSEcCtD
Avanafil—Gastritis—Epirubicin—testicular cancer	0.00253	0.00253	CcSEcCtD
Avanafil—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.00252	0.00252	CcSEcCtD
Avanafil—Body temperature increased—Ifosfamide—testicular cancer	0.00251	0.00251	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.0025	0.0025	CcSEcCtD
Avanafil—Infection—Etoposide—testicular cancer	0.00249	0.00249	CcSEcCtD
Avanafil—Asthenia—Dactinomycin—testicular cancer	0.00249	0.00249	CcSEcCtD
Avanafil—Blood creatinine increased—Doxorubicin—testicular cancer	0.00248	0.00248	CcSEcCtD
Avanafil—Influenza—Epirubicin—testicular cancer	0.00247	0.00247	CcSEcCtD
Avanafil—Upper respiratory tract infection—Methotrexate—testicular cancer	0.00246	0.00246	CcSEcCtD
Avanafil—Tachycardia—Etoposide—testicular cancer	0.00245	0.00245	CcSEcCtD
Avanafil—Skin disorder—Etoposide—testicular cancer	0.00244	0.00244	CcSEcCtD
Avanafil—Angina pectoris—Epirubicin—testicular cancer	0.00241	0.00241	CcSEcCtD
Avanafil—Breast disorder—Doxorubicin—testicular cancer	0.00239	0.00239	CcSEcCtD
Avanafil—Bronchitis—Epirubicin—testicular cancer	0.00238	0.00238	CcSEcCtD
Avanafil—Diarrhoea—Dactinomycin—testicular cancer	0.00237	0.00237	CcSEcCtD
Avanafil—Nasopharyngitis—Doxorubicin—testicular cancer	0.00237	0.00237	CcSEcCtD
Avanafil—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00236	0.00236	CcSEcCtD
Avanafil—Vomiting—Bleomycin—testicular cancer	0.00236	0.00236	CcSEcCtD
Avanafil—Infestation NOS—Methotrexate—testicular cancer	0.00236	0.00236	CcSEcCtD
Avanafil—Infestation—Methotrexate—testicular cancer	0.00236	0.00236	CcSEcCtD
Avanafil—Hypotension—Etoposide—testicular cancer	0.00234	0.00234	CcSEcCtD
Avanafil—Rash—Bleomycin—testicular cancer	0.00234	0.00234	CcSEcCtD
Avanafil—Gastritis—Doxorubicin—testicular cancer	0.00234	0.00234	CcSEcCtD
Avanafil—Dermatitis—Bleomycin—testicular cancer	0.00234	0.00234	CcSEcCtD
Avanafil—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.00234	0.00234	CcSEcCtD
Avanafil—Upper respiratory tract infection—Epirubicin—testicular cancer	0.0023	0.0023	CcSEcCtD
Avanafil—Influenza—Doxorubicin—testicular cancer	0.00229	0.00229	CcSEcCtD
Avanafil—Pollakiuria—Epirubicin—testicular cancer	0.00229	0.00229	CcSEcCtD
Avanafil—Asthenia—Ifosfamide—testicular cancer	0.00228	0.00228	CcSEcCtD
Avanafil—Weight increased—Epirubicin—testicular cancer	0.00225	0.00225	CcSEcCtD
Avanafil—Pruritus—Ifosfamide—testicular cancer	0.00225	0.00225	CcSEcCtD
Avanafil—Haematuria—Methotrexate—testicular cancer	0.00225	0.00225	CcSEcCtD
Avanafil—Somnolence—Etoposide—testicular cancer	0.00223	0.00223	CcSEcCtD
Avanafil—Angina pectoris—Doxorubicin—testicular cancer	0.00223	0.00223	CcSEcCtD
Avanafil—Epistaxis—Methotrexate—testicular cancer	0.00222	0.00222	CcSEcCtD
Avanafil—Nausea—Bleomycin—testicular cancer	0.00221	0.00221	CcSEcCtD
Avanafil—Infestation—Epirubicin—testicular cancer	0.00221	0.00221	CcSEcCtD
Avanafil—Infestation NOS—Epirubicin—testicular cancer	0.00221	0.00221	CcSEcCtD
Avanafil—Vomiting—Dactinomycin—testicular cancer	0.0022	0.0022	CcSEcCtD
Avanafil—Bronchitis—Doxorubicin—testicular cancer	0.0022	0.0022	CcSEcCtD
Avanafil—Rash—Dactinomycin—testicular cancer	0.00219	0.00219	CcSEcCtD
Avanafil—Diarrhoea—Ifosfamide—testicular cancer	0.00217	0.00217	CcSEcCtD
Avanafil—Gastrointestinal disorder—Etoposide—testicular cancer	0.00217	0.00217	CcSEcCtD
Avanafil—Body temperature increased—Cisplatin—testicular cancer	0.00217	0.00217	CcSEcCtD
Avanafil—Fatigue—Etoposide—testicular cancer	0.00216	0.00216	CcSEcCtD
Avanafil—Constipation—Etoposide—testicular cancer	0.00215	0.00215	CcSEcCtD
Avanafil—Urinary tract infection—Epirubicin—testicular cancer	0.00214	0.00214	CcSEcCtD
Avanafil—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.00213	0.00213	CcSEcCtD
Avanafil—Pollakiuria—Doxorubicin—testicular cancer	0.00211	0.00211	CcSEcCtD
Avanafil—Haematuria—Epirubicin—testicular cancer	0.0021	0.0021	CcSEcCtD
Avanafil—Dizziness—Ifosfamide—testicular cancer	0.0021	0.0021	CcSEcCtD
Avanafil—Urinary tract disorder—Methotrexate—testicular cancer	0.00209	0.00209	CcSEcCtD
Avanafil—Weight increased—Doxorubicin—testicular cancer	0.00208	0.00208	CcSEcCtD
Avanafil—Epistaxis—Epirubicin—testicular cancer	0.00208	0.00208	CcSEcCtD
Avanafil—Urethral disorder—Methotrexate—testicular cancer	0.00207	0.00207	CcSEcCtD
Avanafil—Sinusitis—Epirubicin—testicular cancer	0.00207	0.00207	CcSEcCtD
Avanafil—Nausea—Dactinomycin—testicular cancer	0.00206	0.00206	CcSEcCtD
Avanafil—Infestation NOS—Doxorubicin—testicular cancer	0.00204	0.00204	CcSEcCtD
Avanafil—Infestation—Doxorubicin—testicular cancer	0.00204	0.00204	CcSEcCtD
Avanafil—Vomiting—Ifosfamide—testicular cancer	0.00202	0.00202	CcSEcCtD
Avanafil—Rash—Ifosfamide—testicular cancer	0.002	0.002	CcSEcCtD
Avanafil—Dermatitis—Ifosfamide—testicular cancer	0.002	0.002	CcSEcCtD
Avanafil—Body temperature increased—Etoposide—testicular cancer	0.00198	0.00198	CcSEcCtD
Avanafil—Urinary tract infection—Doxorubicin—testicular cancer	0.00198	0.00198	CcSEcCtD
Avanafil—Eye disorder—Methotrexate—testicular cancer	0.00198	0.00198	CcSEcCtD
Avanafil—Asthenia—Cisplatin—testicular cancer	0.00197	0.00197	CcSEcCtD
Avanafil—Cardiac disorder—Methotrexate—testicular cancer	0.00196	0.00196	CcSEcCtD
Avanafil—Urinary tract disorder—Epirubicin—testicular cancer	0.00196	0.00196	CcSEcCtD
Avanafil—Oedema peripheral—Epirubicin—testicular cancer	0.00195	0.00195	CcSEcCtD
Avanafil—Haematuria—Doxorubicin—testicular cancer	0.00195	0.00195	CcSEcCtD
Avanafil—Connective tissue disorder—Epirubicin—testicular cancer	0.00195	0.00195	CcSEcCtD
Avanafil—Urethral disorder—Epirubicin—testicular cancer	0.00194	0.00194	CcSEcCtD
Avanafil—Epistaxis—Doxorubicin—testicular cancer	0.00192	0.00192	CcSEcCtD
Avanafil—Angiopathy—Methotrexate—testicular cancer	0.00192	0.00192	CcSEcCtD
Avanafil—Sinusitis—Doxorubicin—testicular cancer	0.00191	0.00191	CcSEcCtD
Avanafil—Immune system disorder—Methotrexate—testicular cancer	0.00191	0.00191	CcSEcCtD
Avanafil—Mediastinal disorder—Methotrexate—testicular cancer	0.00191	0.00191	CcSEcCtD
Avanafil—Nausea—Ifosfamide—testicular cancer	0.00189	0.00189	CcSEcCtD
Avanafil—Diarrhoea—Cisplatin—testicular cancer	0.00187	0.00187	CcSEcCtD
Avanafil—Mental disorder—Methotrexate—testicular cancer	0.00185	0.00185	CcSEcCtD
Avanafil—Eye disorder—Epirubicin—testicular cancer	0.00185	0.00185	CcSEcCtD
Avanafil—Malnutrition—Methotrexate—testicular cancer	0.00184	0.00184	CcSEcCtD
Avanafil—Flushing—Epirubicin—testicular cancer	0.00184	0.00184	CcSEcCtD
Avanafil—Cardiac disorder—Epirubicin—testicular cancer	0.00184	0.00184	CcSEcCtD
Avanafil—Urinary tract disorder—Doxorubicin—testicular cancer	0.00181	0.00181	CcSEcCtD
Avanafil—Oedema peripheral—Doxorubicin—testicular cancer	0.0018	0.0018	CcSEcCtD
Avanafil—Asthenia—Etoposide—testicular cancer	0.0018	0.0018	CcSEcCtD
Avanafil—Connective tissue disorder—Doxorubicin—testicular cancer	0.0018	0.0018	CcSEcCtD
Avanafil—Angiopathy—Epirubicin—testicular cancer	0.0018	0.0018	CcSEcCtD
Avanafil—Urethral disorder—Doxorubicin—testicular cancer	0.0018	0.0018	CcSEcCtD
Avanafil—Immune system disorder—Epirubicin—testicular cancer	0.00179	0.00179	CcSEcCtD
Avanafil—Mediastinal disorder—Epirubicin—testicular cancer	0.00178	0.00178	CcSEcCtD
Avanafil—Back pain—Methotrexate—testicular cancer	0.00178	0.00178	CcSEcCtD
Avanafil—Pruritus—Etoposide—testicular cancer	0.00178	0.00178	CcSEcCtD
Avanafil—Vomiting—Cisplatin—testicular cancer	0.00174	0.00174	CcSEcCtD
Avanafil—Vision blurred—Methotrexate—testicular cancer	0.00174	0.00174	CcSEcCtD
Avanafil—Mental disorder—Epirubicin—testicular cancer	0.00173	0.00173	CcSEcCtD
Avanafil—Rash—Cisplatin—testicular cancer	0.00173	0.00173	CcSEcCtD
Avanafil—Dermatitis—Cisplatin—testicular cancer	0.00173	0.00173	CcSEcCtD
Avanafil—Malnutrition—Epirubicin—testicular cancer	0.00172	0.00172	CcSEcCtD
Avanafil—Diarrhoea—Etoposide—testicular cancer	0.00172	0.00172	CcSEcCtD
Avanafil—Eye disorder—Doxorubicin—testicular cancer	0.00171	0.00171	CcSEcCtD
Avanafil—Cardiac disorder—Doxorubicin—testicular cancer	0.0017	0.0017	CcSEcCtD
Avanafil—Flushing—Doxorubicin—testicular cancer	0.0017	0.0017	CcSEcCtD
Avanafil—Back pain—Epirubicin—testicular cancer	0.00167	0.00167	CcSEcCtD
Avanafil—Angiopathy—Doxorubicin—testicular cancer	0.00166	0.00166	CcSEcCtD
Avanafil—Dizziness—Etoposide—testicular cancer	0.00166	0.00166	CcSEcCtD
Avanafil—Muscle spasms—Epirubicin—testicular cancer	0.00166	0.00166	CcSEcCtD
Avanafil—Immune system disorder—Doxorubicin—testicular cancer	0.00165	0.00165	CcSEcCtD
Avanafil—Vertigo—Methotrexate—testicular cancer	0.00165	0.00165	CcSEcCtD
Avanafil—Mediastinal disorder—Doxorubicin—testicular cancer	0.00165	0.00165	CcSEcCtD
Avanafil—Nausea—Cisplatin—testicular cancer	0.00163	0.00163	CcSEcCtD
Avanafil—Vision blurred—Epirubicin—testicular cancer	0.00162	0.00162	CcSEcCtD
Avanafil—Cough—Methotrexate—testicular cancer	0.00161	0.00161	CcSEcCtD
Avanafil—Mental disorder—Doxorubicin—testicular cancer	0.00161	0.00161	CcSEcCtD
Avanafil—Vomiting—Etoposide—testicular cancer	0.0016	0.0016	CcSEcCtD
Avanafil—Malnutrition—Doxorubicin—testicular cancer	0.00159	0.00159	CcSEcCtD
Avanafil—Agitation—Epirubicin—testicular cancer	0.00158	0.00158	CcSEcCtD
Avanafil—Rash—Etoposide—testicular cancer	0.00158	0.00158	CcSEcCtD
Avanafil—Dermatitis—Etoposide—testicular cancer	0.00158	0.00158	CcSEcCtD
Avanafil—Headache—Etoposide—testicular cancer	0.00157	0.00157	CcSEcCtD
Avanafil—Arthralgia—Methotrexate—testicular cancer	0.00157	0.00157	CcSEcCtD
Avanafil—Chest pain—Methotrexate—testicular cancer	0.00157	0.00157	CcSEcCtD
Avanafil—Myalgia—Methotrexate—testicular cancer	0.00157	0.00157	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00156	0.00156	CcSEcCtD
Avanafil—Vertigo—Epirubicin—testicular cancer	0.00155	0.00155	CcSEcCtD
Avanafil—Back pain—Doxorubicin—testicular cancer	0.00154	0.00154	CcSEcCtD
Avanafil—Muscle spasms—Doxorubicin—testicular cancer	0.00153	0.00153	CcSEcCtD
Avanafil—Palpitations—Epirubicin—testicular cancer	0.00152	0.00152	CcSEcCtD
Avanafil—Cough—Epirubicin—testicular cancer	0.0015	0.0015	CcSEcCtD
Avanafil—Vision blurred—Doxorubicin—testicular cancer	0.0015	0.0015	CcSEcCtD
Avanafil—Infection—Methotrexate—testicular cancer	0.00149	0.00149	CcSEcCtD
Avanafil—Nausea—Etoposide—testicular cancer	0.00149	0.00149	CcSEcCtD
Avanafil—Hypertension—Epirubicin—testicular cancer	0.00149	0.00149	CcSEcCtD
Avanafil—Nervous system disorder—Methotrexate—testicular cancer	0.00147	0.00147	CcSEcCtD
Avanafil—Arthralgia—Epirubicin—testicular cancer	0.00147	0.00147	CcSEcCtD
Avanafil—Chest pain—Epirubicin—testicular cancer	0.00147	0.00147	CcSEcCtD
Avanafil—Myalgia—Epirubicin—testicular cancer	0.00147	0.00147	CcSEcCtD
Avanafil—Agitation—Doxorubicin—testicular cancer	0.00147	0.00147	CcSEcCtD
Avanafil—Skin disorder—Methotrexate—testicular cancer	0.00146	0.00146	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00146	0.00146	CcSEcCtD
Avanafil—Dry mouth—Epirubicin—testicular cancer	0.00144	0.00144	CcSEcCtD
Avanafil—Vertigo—Doxorubicin—testicular cancer	0.00143	0.00143	CcSEcCtD
Avanafil—Palpitations—Doxorubicin—testicular cancer	0.00141	0.00141	CcSEcCtD
Avanafil—Hypotension—Methotrexate—testicular cancer	0.0014	0.0014	CcSEcCtD
Avanafil—Infection—Epirubicin—testicular cancer	0.0014	0.0014	CcSEcCtD
Avanafil—Cough—Doxorubicin—testicular cancer	0.00139	0.00139	CcSEcCtD
Avanafil—Nervous system disorder—Epirubicin—testicular cancer	0.00138	0.00138	CcSEcCtD
Avanafil—Hypertension—Doxorubicin—testicular cancer	0.00138	0.00138	CcSEcCtD
Avanafil—Tachycardia—Epirubicin—testicular cancer	0.00137	0.00137	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.00137	0.00137	CcSEcCtD
Avanafil—Skin disorder—Epirubicin—testicular cancer	0.00137	0.00137	CcSEcCtD
Avanafil—Insomnia—Methotrexate—testicular cancer	0.00136	0.00136	CcSEcCtD
Avanafil—Arthralgia—Doxorubicin—testicular cancer	0.00136	0.00136	CcSEcCtD
Avanafil—Chest pain—Doxorubicin—testicular cancer	0.00136	0.00136	CcSEcCtD
Avanafil—Myalgia—Doxorubicin—testicular cancer	0.00136	0.00136	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.00135	0.00135	CcSEcCtD
Avanafil—Somnolence—Methotrexate—testicular cancer	0.00134	0.00134	CcSEcCtD
Avanafil—Dry mouth—Doxorubicin—testicular cancer	0.00133	0.00133	CcSEcCtD
Avanafil—Dyspepsia—Methotrexate—testicular cancer	0.00132	0.00132	CcSEcCtD
Avanafil—Hypotension—Epirubicin—testicular cancer	0.00131	0.00131	CcSEcCtD
Avanafil—Gastrointestinal disorder—Methotrexate—testicular cancer	0.0013	0.0013	CcSEcCtD
Avanafil—Fatigue—Methotrexate—testicular cancer	0.0013	0.0013	CcSEcCtD
Avanafil—Infection—Doxorubicin—testicular cancer	0.00129	0.00129	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.00128	0.00128	CcSEcCtD
Avanafil—Nervous system disorder—Doxorubicin—testicular cancer	0.00128	0.00128	CcSEcCtD
Avanafil—Insomnia—Epirubicin—testicular cancer	0.00127	0.00127	CcSEcCtD
Avanafil—Tachycardia—Doxorubicin—testicular cancer	0.00127	0.00127	CcSEcCtD
Avanafil—Skin disorder—Doxorubicin—testicular cancer	0.00126	0.00126	CcSEcCtD
Avanafil—Somnolence—Epirubicin—testicular cancer	0.00125	0.00125	CcSEcCtD
Avanafil—Dyspepsia—Epirubicin—testicular cancer	0.00124	0.00124	CcSEcCtD
Avanafil—Hypotension—Doxorubicin—testicular cancer	0.00122	0.00122	CcSEcCtD
Avanafil—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00121	0.00121	CcSEcCtD
Avanafil—Fatigue—Epirubicin—testicular cancer	0.00121	0.00121	CcSEcCtD
Avanafil—Constipation—Epirubicin—testicular cancer	0.0012	0.0012	CcSEcCtD
Avanafil—Body temperature increased—Methotrexate—testicular cancer	0.00119	0.00119	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.00119	0.00119	CcSEcCtD
Avanafil—Insomnia—Doxorubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Avanafil—Somnolence—Doxorubicin—testicular cancer	0.00116	0.00116	CcSEcCtD
Avanafil—Dyspepsia—Doxorubicin—testicular cancer	0.00115	0.00115	CcSEcCtD
Avanafil—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Avanafil—Fatigue—Doxorubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Avanafil—Constipation—Doxorubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Avanafil—Body temperature increased—Epirubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Avanafil—Asthenia—Methotrexate—testicular cancer	0.00108	0.00108	CcSEcCtD
Avanafil—Pruritus—Methotrexate—testicular cancer	0.00106	0.00106	CcSEcCtD
Avanafil—Body temperature increased—Doxorubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Avanafil—Diarrhoea—Methotrexate—testicular cancer	0.00103	0.00103	CcSEcCtD
Avanafil—Asthenia—Epirubicin—testicular cancer	0.00101	0.00101	CcSEcCtD
Avanafil—Pruritus—Epirubicin—testicular cancer	0.000995	0.000995	CcSEcCtD
Avanafil—Dizziness—Methotrexate—testicular cancer	0.000994	0.000994	CcSEcCtD
Avanafil—Diarrhoea—Epirubicin—testicular cancer	0.000962	0.000962	CcSEcCtD
Avanafil—Vomiting—Methotrexate—testicular cancer	0.000956	0.000956	CcSEcCtD
Avanafil—Rash—Methotrexate—testicular cancer	0.000948	0.000948	CcSEcCtD
Avanafil—Dermatitis—Methotrexate—testicular cancer	0.000947	0.000947	CcSEcCtD
Avanafil—Headache—Methotrexate—testicular cancer	0.000942	0.000942	CcSEcCtD
Avanafil—Asthenia—Doxorubicin—testicular cancer	0.000934	0.000934	CcSEcCtD
Avanafil—Dizziness—Epirubicin—testicular cancer	0.00093	0.00093	CcSEcCtD
Avanafil—Pruritus—Doxorubicin—testicular cancer	0.000921	0.000921	CcSEcCtD
Avanafil—Vomiting—Epirubicin—testicular cancer	0.000894	0.000894	CcSEcCtD
Avanafil—Nausea—Methotrexate—testicular cancer	0.000893	0.000893	CcSEcCtD
Avanafil—Diarrhoea—Doxorubicin—testicular cancer	0.000891	0.000891	CcSEcCtD
Avanafil—Rash—Epirubicin—testicular cancer	0.000887	0.000887	CcSEcCtD
Avanafil—Dermatitis—Epirubicin—testicular cancer	0.000886	0.000886	CcSEcCtD
Avanafil—Headache—Epirubicin—testicular cancer	0.000881	0.000881	CcSEcCtD
Avanafil—Dizziness—Doxorubicin—testicular cancer	0.000861	0.000861	CcSEcCtD
Avanafil—Nausea—Epirubicin—testicular cancer	0.000836	0.000836	CcSEcCtD
Avanafil—Vomiting—Doxorubicin—testicular cancer	0.000828	0.000828	CcSEcCtD
Avanafil—Rash—Doxorubicin—testicular cancer	0.000821	0.000821	CcSEcCtD
Avanafil—Dermatitis—Doxorubicin—testicular cancer	0.00082	0.00082	CcSEcCtD
Avanafil—Headache—Doxorubicin—testicular cancer	0.000815	0.000815	CcSEcCtD
Avanafil—Nausea—Doxorubicin—testicular cancer	0.000773	0.000773	CcSEcCtD
